Multicomponent reactions as a privileged tool for multitarget-directed ligand strategies in Alzheimer's disease therapy.

Alzheimer’s disease multicomponent reactions multitarget-directed ligand strategy

Journal

Future medicinal chemistry
ISSN: 1756-8927
Titre abrégé: Future Med Chem
Pays: England
ID NLM: 101511162

Informations de publication

Date de publication:
11 2022
Historique:
pubmed: 21 10 2022
medline: 4 11 2022
entrez: 20 10 2022
Statut: ppublish

Résumé

Among neurodegenerative pathologies affecting the older population, Alzheimer's disease is the most common type of dementia and leads to neurocognitive and behavioral disorders. It is a complex and progressive age-related multifactorial disease characterized by a series of highly interconnected pathophysiological processes. Within the last decade, the multitarget-directed ligand strategy has emerged as a viable approach to developing complex molecules that exhibit several pharmacophores which can target the different enzymes and receptors involved in the pathogenesis of the disease. Herein, we focus on using multicomponent reactions such as Hantzsch, Biginelli and Ugi to develop these biologically active multitopic ligands.

Identifiants

pubmed: 36263996
doi: 10.4155/fmc-2022-0170
doi:

Substances chimiques

Ligands 0
Cholinesterase Inhibitors 0

Types de publication

Journal Article Review

Langues

eng

Sous-ensembles de citation

IM

Pagination

1583-1606

Auteurs

Sylvain Grosjean (S)

Laboratoire de Recherches Intégratives en Neurosciences et Psychologie Cognitive (UR-LINC / EA481) - Groupe Chimie Médicinale, Université de Bourgogne Franche-Comté, UFR Santé, 19 rue Ambroise Paré, Besançon, 25000, France.

Irene Pachón-Angona (I)

Laboratoire de Recherches Intégratives en Neurosciences et Psychologie Cognitive (UR-LINC / EA481) - Groupe Chimie Médicinale, Université de Bourgogne Franche-Comté, UFR Santé, 19 rue Ambroise Paré, Besançon, 25000, France.
Current address: Institute of Pharmaceutical Sciences - Computer-Assisted Drug Design, ETH Zurich, Vladimir-Prelog-Weg 1-5/10, Zurich, CH-8093, Switzerland.

Michella Dawra (M)

Laboratoire de Recherches Intégratives en Neurosciences et Psychologie Cognitive (UR-LINC / EA481) - Groupe Chimie Médicinale, Université de Bourgogne Franche-Comté, UFR Santé, 19 rue Ambroise Paré, Besançon, 25000, France.

Bernard Refouvelet (B)

Laboratoire de Recherches Intégratives en Neurosciences et Psychologie Cognitive (UR-LINC / EA481) - Groupe Chimie Médicinale, Université de Bourgogne Franche-Comté, UFR Santé, 19 rue Ambroise Paré, Besançon, 25000, France.

Lhassane Ismaili (L)

Laboratoire de Recherches Intégratives en Neurosciences et Psychologie Cognitive (UR-LINC / EA481) - Groupe Chimie Médicinale, Université de Bourgogne Franche-Comté, UFR Santé, 19 rue Ambroise Paré, Besançon, 25000, France.

Articles similaires

[Redispensing of expensive oral anticancer medicines: a practical application].

Lisanne N van Merendonk, Kübra Akgöl, Bastiaan Nuijen
1.00
Humans Antineoplastic Agents Administration, Oral Drug Costs Counterfeit Drugs

Smoking Cessation and Incident Cardiovascular Disease.

Jun Hwan Cho, Seung Yong Shin, Hoseob Kim et al.
1.00
Humans Male Smoking Cessation Cardiovascular Diseases Female
Humans United States Aged Cross-Sectional Studies Medicare Part C
1.00
Humans Yoga Low Back Pain Female Male

Classifications MeSH